{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:34:45Z","timestamp":1780601685927,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1245\/s10434-025-18618-6","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:33:38Z","timestamp":1761852818000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy"],"prefix":"10.1245","volume":"33","author":[{"given":"Michelle M.","family":"Dugan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"Balsay-Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Israeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly R.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Wayne","family":"Cruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogerio I.","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amod A.","family":"Sarnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad A.","family":"Tarhini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Brohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Eroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilit","family":"Karapetyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Y.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6886-4468","authenticated-orcid":false,"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"18618_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpsurg.2024.101565","volume":"62","author":"MM Dugan","year":"2025","unstructured":"Dugan MM, Shannon AB, DePalo DK, et al. Current management of nonmelanoma skin cancers. Curr Probl Surg. 2025;62:101565. https:\/\/doi.org\/10.1016\/j.cpsurg.2024.101565.","journal-title":"Curr Probl Surg."},{"issue":"6","key":"18618_CR2","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1245\/s10434-019-08187-w","volume":"27","author":"CR Farley","year":"2020","unstructured":"Farley CR, Perez MC, Soelling SJ, et al. Merkel cell carcinoma outcomes: Does ajcc8 underestimate survival? Ann Surg Oncol. 2020;27(6):1978\u201385. https:\/\/doi.org\/10.1245\/s10434-019-08187-w.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"18618_CR3","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","volume":"158","author":"AM McEvoy","year":"2022","unstructured":"McEvoy AM, Lachance K, Hippe DS, et al. Recurrence and mortality risk of merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol. 2022;158(4):382\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2021.6096.","journal-title":"JAMA Dermatol."},{"issue":"11","key":"18618_CR4","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.1245\/s10434-022-12201-z","volume":"29","author":"AB Shannon","year":"2022","unstructured":"Shannon AB, Straker RJ 3rd, Carr MJ, et al. An internally validated prognostic risk-score model for disease-specific survival in clinical stage i and ii merkel cell carcinoma. Ann Surg Oncol. 2022;29(11):7033\u201344. https:\/\/doi.org\/10.1245\/s10434-022-12201-z.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"18618_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jaad.2017.12.001","volume":"78","author":"K Coggshall","year":"2018","unstructured":"Coggshall K, Tello TL, North JP, Yu SS. Merkel cell carcinoma: an update and review: pathogenesis, diagnosis, and staging. J Am Acad Dermatol. 2018;78(3):433\u201342. https:\/\/doi.org\/10.1016\/j.jaad.2017.12.001.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"18618_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/bjd\/ljad404","volume":"190","author":"ST Mohsen","year":"2024","unstructured":"Mohsen ST, Price EL, Chan AW, et al. Incidence, mortality and survival of merkel cell carcinoma: a systematic review of population-based studies. Br J Dermatol. 2024;190(6):811\u201324. https:\/\/doi.org\/10.1093\/bjd\/ljad404.","journal-title":"Br J Dermatol."},{"issue":"3","key":"18618_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","volume":"78","author":"KG Paulson","year":"2018","unstructured":"Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: current us incidence and projected increases based on changing demographics. J Am Acad Dermatol. 2018;78(3):457\u201363. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.028.","journal-title":"J Am Acad Dermatol."},{"issue":"1D","key":"18618_CR8","doi-asserted-by":"publisher","first-page":"e240002","DOI":"10.6004\/jnccn.2024.0002","volume":"22","author":"CD Schmults","year":"2024","unstructured":"Schmults CD, Blitzblau R, Aasi SZ, et al. Nccn guidelines(r) insights: Merkel cell carcinoma, version 1.2024. J Natl Compr Canc Netw. 2024;22(1D):e240002. https:\/\/doi.org\/10.6004\/jnccn.2024.0002.","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"18618_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-virology-011720-121757","volume":"7","author":"W Liu","year":"2020","unstructured":"Liu W, You J. Molecular mechanisms of merkel cell polyomavirus transformation and replication. Annu Rev Virol. 2020;7(1):289\u2013307. https:\/\/doi.org\/10.1146\/annurev-virology-011720-121757.","journal-title":"Annu Rev Virol."},{"issue":"19","key":"18618_CR10","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-18-4159","volume":"25","author":"TC Knepper","year":"2019","unstructured":"Knepper TC, Montesion M, Russell JS, et al. The genomic landscape of merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy. Clin Cancer Res. 2019;25(19):5961\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4159.","journal-title":"Clin Cancer Res."},{"issue":"18","key":"18618_CR11","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1002\/cncr.29452","volume":"121","author":"FO Smith","year":"2015","unstructured":"Smith FO, Yue B, Marzban SS, et al. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in merkel cell carcinoma. Cancer. 2015;121(18):3252\u201360. https:\/\/doi.org\/10.1002\/cncr.29452.","journal-title":"Cancer."},{"issue":"2","key":"18618_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14240","volume":"174","author":"DA Gunaratne","year":"2016","unstructured":"Gunaratne DA, Howle JR, Veness MJ. Sentinel lymph node biopsy in merkel cell carcinoma: a 15-year institutional experience and statistical analysis of 721 reported cases. Br J Dermatol. 2016;174(2):273\u201381. https:\/\/doi.org\/10.1111\/bjd.14240.","journal-title":"Br J Dermatol."},{"key":"18618_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","volume":"171","author":"ML Gauci","year":"2022","unstructured":"Gauci ML, Aristei C, Becker JC, et al. Diagnosis and treatment of merkel cell carcinoma: European consensus-based interdisciplinary guideline\u2014update 2022. Eur J Cancer. 2022;171:203\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.043.","journal-title":"Eur J Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18618-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18618-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18618-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:09:12Z","timestamp":1765289352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18618-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18618"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18618-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Ricardo J. Gonzalez, Dr. C. Wayne Cruse, Dr. Jane L. Messina, Dr. Rogerio I. Neves, Dr. Michael Harrington, Dr. Michelle M. Dugan, Dr. Caitlyn Balsay-Patel, Nicholas Chin, Jacob Israeli, Kimberly R. Ward, Matthew Nichols, Stephanie Forgas, and Wenyi Fan have no conflicts of interest or financial ties to disclose. Dr. Matthew C. Perez has received consulting fees from Guidepoint, Replimune. Dr. Amod A. Sarnaik has received consulting fees: Blueprint Oncology Concepts, Gerson Lehrman Group, Guidepoint, Iovance Biotherapeutics, Second City Science. Grants\/Contracts: Iovance Biotherapeutics, Provectus Biopharmaceuticals, Turnstone Biologics. Patents, Royalties: Moffitt Cancer Center (licensed from Iovance Biotherapeutics), Provectus Biopharmaceuticals. Speaker honoraria: Clinical Education Alliance, MJH Holdings, International workshop CAR-T, Society for the Immunotherapy of Cancer. Dr. Vernon K. Sondak serves in a consulting or advisory role for Merck\/Schering Plough, Novartis, Bristol Myers Squibb, Regeneron, Iovance Biotherapeutics, Alkermes, Ultimovacs, Genesis Drug Discovery & Development, and Sun Pharma. He has received research funding to the institution (Moffitt Cancer Center) from Neogene Therapeutics, Turnstone Bio, and Skyline Diagnostics, not related to this research. Dr. Ahmad A. Tarhini has a consulting or Advisory Role: Bristol Myers Squibb, Merck, Genentech\/Roche, Moderna, Novartis, Sanofi Genzyme, Regeneron, Partner Therapeutics, Clinigen Group, Eisai, Bayer, Instil Bio, and ConcertAI. Research Funding (Contracted with institution): OncoSec, Bristol Myers Squibb, Merck, Genentech\/Roche, OncoSec, Sanofi\/Regeneron, Iovance, InflaRx, Acrotech Biopharma, Pfizer (Inst), Agenus, Dragonfly, Werewolf and Scholar Rock. Dr. Nikhil Khushalani owns stock in Amarin Pharma Inc., Asensus Surgical, and Bellicum Pharmaceuticals. He has participated in data and safety monitoring for AstraZeneca and Incyte Corporation. He has served as a consultant for Bristol Myers Squibb, Castle Biosciences, Genzyme, Immunocore, Instil Bio, IO Biotech, Iovance Biotherapeutics, Jounce, Merck, Mural Oncology, MyCareGorithm, Nektar, Novartis, Regeneron Pharmaceuticals, Replimune. He has received research funding (all to Institue) from BMS, Merck, Celgene, GSK, HUYABIO international, Replimune, Regeneron, Novartis, IDEAYA, Modulation Therapeutics. Dr. Andrew S. Brohl has received payments from Deciphera - Advisory Board, and has received research funding from Merck. Dr. Joseph Markowitz has received grants from Bankhead Coley and the NIH that are unrelated to this study. Additionally, he has industry support from Merck for a trial that is outside the scope of this submitted work. He also has a provisional patent pending with Moffitt Cancer Center that is not related to this study. Dr. Zeynep Eroglu is on Advisory boards: Pfizer, Replimune, SunPharma, Natera, Novartis, Regeneron, Incyte Research funding: Boehringer Ingelheim, Pfizer. Dr. Lilit Karapetyan has received Research support Iovance Biotherapeutics to Institution, Valar labs to Institution. Traveling support Immatics. Dr. Kenneth Y. Tsai has consulting agreements with Verrica Pharmaceuticals, Senhwa Biosciences, NFlection Therapeutics, Almirall, and has received research funding from Incyte Corporation and Merck. Dr. Jonathan S. Zager has received payments from Delcath Systems \u2013 Medical Advisory Board. He has consulting agreements with Philogen, Merit Medical, Castle Biosciences, and Merck. His department receives research funding from\u00a0Philogen, SWOG, Delcath Systems, and Provectus. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}